吗替麦考酚酯治疗免疫相关性皮肤病专家建议

doi:10.35541/cjd.20200306

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (11): 869-874.doi: 10.35541/cjd.20200306

吗替麦考酚酯治疗免疫相关性皮肤病专家建议

中国医师协会皮肤科医师分会自身免疫性疾病专业委员会

中国医师协会皮肤科医师分会自身免疫性疾病专业委员会

收稿日期:2020-03-30 修回日期:2020-06-12 发布日期:2020-11-03
通讯作者: 邓丹琪；左亚刚 E-mail:danqid128@sina.com;zuoyagang@263.net

Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal

Committee on Autoimmune Diseases, China Dermatologist Association

Committee on Autoimmune Diseases, China Dermatologist Association

Received:2020-03-30 Revised:2020-06-12 Published:2020-11-03
Contact: Deng Danqi; Zuo Yagang E-mail:danqid128@sina.com;zuoyagang@263.net

摘要/Abstract

摘要： 【摘要】吗替麦考酚酯可选择性抑制T、B淋巴细胞的增殖和活性，已广泛应用于多种免疫相关性皮肤病的治疗。在检索国内外文献的基础上，中国不同地域多位专家讨论和撰写了本建议。根据英国牛津大学循证医学中心制定的推荐等级标准，吗替麦考酚酯在成人中重度寻常型斑块状银屑病、成人大疱性类天疱疮和寻常型天疱疮的治疗中属于A级推荐；在成人系统性硬化症、成人中重度湿疹和中重度特应性皮炎的治疗中均属于B级推荐；在皮肤型红斑狼疮、皮肌炎、无肌病性皮肌炎、儿童系统性硬化症、儿童大疱性类天疱疮和儿童天疱疮、儿童中重度湿疹和特应性皮炎的治疗中属于C级推荐。

关键词: 自身免疫疾病, 银屑病, 类天疱疮, 大疱性, 天疱疮, 硬皮病, 系统性, 皮炎, 皮肌炎, 吗替麦考酚酯

Abstract: 【Abstract】 Mycophenolate mofetil can selectively inhibit the proliferation and activity of T and B lymphocytes, and has been widely used in the treatment of a variety of immune-related skin diseases. On the basis of Chinese and international literature, a proposal was formed after discussion among multiple experts from different regions in China. According to the criteria for grading the strength of recommendations established by the Oxford Centre for Evidence-based Medicine, the strength of recommendation is grade A for use of mycophenolate mofetil in the treatment of moderate to severe adult plaque psoriasis vulgaris, adult bullous pemphigoid and pemphigus vulgaris, grade B for use of mycophenolate mofetil in the treatment of adult systemic sclerosis, moderate to severe adult eczema and moderate to severe atopic dermatitis, and grade C for use of mycophenolate mofetil in the treatment of cutaneous lupus erythematosus, dermatomyositis, amyopathic dermatomyositis, childhood systemic sclerosis, childhood bullous pemphigoid and childhood pemphigus, moderate to severe childhood eczema and atopic dermatitis.

Key words: Autoimmune diseases, Psoriasis, Pemphigoid, bullous, Pemphigus, Scleroderma, systemic, Dermatitis, Dermatomyositis, Mycophenolate mofetil

中国医师协会皮肤科医师分会自身免疫性疾病专业委员会. 吗替麦考酚酯治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2020,53(11):869-874. doi:10.35541/cjd.20200306

Committee on Autoimmune Diseases, China Dermatologist Association. Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal[J]. Chinese Journal of Dermatology, 2020, 53(11): 869-874.doi:10.35541/cjd.20200306

参考文献 49

［1］	吗替麦考酚酯在肾内科应用专家共识组. 吗替麦考酚酯在肾内科应用专家共识——2006年第四次修订［J］. 中华内科杂志, 2006,45（11）:965⁃966. doi: 10.3760/j.issn:0578⁃1426.2006. 11.036.
［2］	吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识小组. 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识［J］. 中华风湿病学杂志, 2019,23（7）:436⁃440. doi: 10. 3760/cma.j.issn.1007⁃7480.2019.07.002.
［3］	Thervet E, Anglicheau D, Legendre C. Pharmacology of mycophenolate mofetil: recent data and clinical consequences［J］. Nephrologie, 2001,22（7）:331⁃337.
［4］	Liu YX, Jin LM, Zhou L, et al. Mycophenolate mofetil attenuates liver ischemia/reperfusion injury in rats［J］. Transpl Int, 2009,22（7）:747⁃756. doi: 10.1111/j.1432⁃2277.2009.00866.x.
［5］	Nakaseko H, Iwata N, Yasuoka R, et al. Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases［J］. Mod Rheumatol, 2019,29（6）:1002⁃1006. doi: 10. 1080/14397595.2018.1532785.
［6］	Li H, Mager DE, Sandmaier BM, et al. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil［J］. J Clin Pharmacol, 2013,53（4）:393⁃402. doi: 10.1002/jcph.14.
［7］	Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics［J］. Clin Transplant, 2000,14（3）:179⁃188. doi: 10.1034/j.1399⁃0012.2000.140301.x.
［8］	Kuhn A, Aberer E, Bata⁃Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus ⁃ guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:389⁃404. doi: 10.1111/jdv.14053.
［9］	Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid⁃sparing therapy for recalcitrant dermatomyositis［J］. Arch Dermatol, 2006,142（1）:65⁃69. doi: 10.1001/archderm.142.1.65.
［10］	Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists［J］. Mod Rheumatol, 2019,29（1）:1⁃19. doi: 10.1080/14397595.2018.15 21185.
［11］	Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. J Dtsch Dermatol Ges, 2016,14（3）:321⁃338. doi: 10.1111/ddg.12909.
［12］	Cozzani E, Cinotti E, Felletti R, et al. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil［J］. Immunopharmacol Immunotoxicol, 2013,35（6）:687⁃692. doi: 10.3109/08923973.2013.833624.
［13］	Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti⁃MDA⁃5 antibodies［J］. Clin Rheumatol, 2017,36（1）:239⁃240. doi: 10.1007/s10067⁃016⁃3443⁃2.
［14］	Koyama R, Braga T, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case⁃based review［J］. Clin Rheumatol, 2017,36（8）:1919⁃1926. doi: 10.1007/s10067⁃017⁃3671⁃0.
［15］	Bellutti Enders F, Bader⁃Meunier B, Baildam E, et al. Consensus⁃based recommendations for the management of juvenile dermatomyositis［J］. Ann Rheum Dis, 2017,76（2）:329⁃340. doi: 10.1136/annrheumdis⁃2016⁃209247.
［16］	Taroni JN, Martyanov V, Mahoney JM, et al. A functional genomic meta⁃analysis of clinical trials in systemic sclerosis: toward precision medicine and combination therapy［J］. J Invest Dermatol, 2017,137（5）:1033⁃1041. doi: 10.1016/j.jid.2016.12. 007.
［17］	Gale SL, Trinh H, Mathew N, et al. Characterizing disease manifestations and treatment patterns among adults with systemic sclerosis: a retrospective analysis of a US healthcare claims population［J］. Rheumatol Ther, 2020,7（1）:89⁃99. doi:10.1007/s40744⁃019⁃00181⁃8.
［18］	Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma⁃related interstitial lung disease （SLS II）: a randomised controlled, double⁃blind, parallel group trial［J］. Lancet Respir Med, 2016,4（9）:708⁃719. doi: 10.1016/S2213⁃2600（16）30152⁃7.
［19］	Mendoza FA, Lee⁃Ching C, Jimenez SA. Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate mofetil treatment in patients with diffuse systemic sclerosis［J］. Semin Arthritis Rheum, 2020,50（1）:135⁃139. doi: 10.1016/j.semarthrit.2019.06.012.
［20］	Kowal⁃Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis［J］. Ann Rheum Dis, 2017,76（8）:1327⁃1339. doi: 10.1136/annrheumdis⁃2016⁃209909.
［21］	Asano Y, Jinnin M, Kawaguchi Y, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis［J］. J Dermatol, 2018,45（6）:633⁃691. doi: 10.1111/1346⁃8138.14162.
［22］	Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis［J］. Nat Rev Rheumatol, 2011,7（11）:676⁃680. doi: 10.1038/nrrheum.2011.148.
［23］	Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology［J］. Br J Dermatol, 2015,172（4）:867⁃877. doi: 10.1111/bjd.13717.
［24］	Cozzani E, Marzano AV, Caproni M, et al. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines［J］. G Ital Dermatol Venereol, 2018,153（3）:305⁃315. doi: 10.23736/S0392⁃0488.18.06006⁃6.
［25］	Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:33⁃47. doi: 10.1590/abd1806⁃4841.2019940207.
［26］	Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid［J］. J Dtsch Dermatol Ges, 2015,13（8）:833⁃844. doi: 10.1111/ddg.12606.
［27］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会. 大疱性类天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（6）:384⁃387. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.06.003.
［28］	Seminario⁃Vidal L, Sami N, Miller J, et al. Mycophenolate mofetil therapy for pediatric bullous pemphigoid［J］. Dermatol Online J, 2015,21（8）:13030/qt3x5585zn.
［29］	Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2015,29（3）:405⁃414. doi: 10.1111/jdv.12772.
［30］	Feliciani C, Cozzani E, Marzano AV, et al. Italian guidelines in pemphigus⁃adapted from the European Dermatology Forum （EDF） and European Academy of Dermatology and Venerology （EADV）［J］. G Ital Dermatol Venereol, 2018,153（5）:599⁃608. doi: 10.23736/S0392⁃0488.18.06073⁃X.
［31］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［32］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［33］	Baratta A, Camarillo D, Papa C, et al. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil （MMF）［J］. Pediatr Dermatol, 2013,30（2）:240⁃244. doi: 10.1111/j.1525⁃1470.2012.01730.x.
［34］	Haeck IM, Knol MJ, Ten Berge O, et al. Enteric⁃coated mycophenolate sodium versus cyclosporin A as long⁃term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial［J］. J Am Acad Dermatol, 2011,64（6）:1074⁃1084. doi: 10.1016/j.jaad.2010.04.027.
［35］	Prussick L, Plotnikova N, Gottlieb A. Mycophenolate mofetil in severe atopic dermatitis: a review［J］. J Drugs Dermatol, 2016,15（6）:715⁃718.
［36］	Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients［J］. J Eur Acad Dermatol Venereol, 2016,30（5）:729⁃747. doi: 10.1111/jdv.13599.
［37］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part Ⅱ［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv.14888.
［38］	Heller M, Shin HT, Orlow SJ, et al. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients［J］. Br J Dermatol, 2007,157（1）:127⁃132. doi: 10.1111/j.1365⁃2133.2007.07947.x.
［39］	Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil［J］. Pediatr Dermatol, 2011,28（6）:689⁃694. doi: 10. 1111/j.1525⁃1470.2011.01488.x.
［40］	Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents［J］. J Am Acad Dermatol, 2009,61（3）:451⁃485. doi: 10.1016/j.jaad.2009.03.027.
［41］	Akhyani M, Chams⁃Davatchi C, Hemami MR, et al. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2010,24（12）:1447⁃1451. doi: 10.1111/j.1468⁃3083. 2010.03667.x.
［42］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. doi: 10.35541/cjd.20190847.
［43］	Liu V, Mackool BT. Mycophenolate in dermatology［J］. J Dermatolog Treat, 2003,14（4）:203⁃211. doi: 10.1080/0954663 0310016826.
［44］	US FDA. Highlights of prescribing information: CELLCEPT®［EB/OL］. （2018⁃08⁃30）［2020⁃06⁃12］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050722s040,050723s041,050758s037,050759s045lbl.pdf.
［45］	Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis［J］. Arthritis Care Res （Hoboken）, 2012,64（6）:797⁃808. doi: 10.1002/acr.21664.
［46］	Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association （EULAR/ERA⁃EDTA） recommendations for the management of adult and paediatric lupus nephritis［J］. Ann Rheum Dis, 2012,71（11）:1771⁃1782. doi: 10.1136/annrheumdis⁃2012⁃201940.
［47］	Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic acid and its pharmacokinetic drug⁃drug interactions in humans: review of the evidence and clinical implications［J］. J Clin Pharmacol, 2020,60（3）:295⁃311. doi: 10.1002/jcph.1565.
［48］	Kuypers DR, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate⁃glucuronosyltransferase［J］. Clin Pharmacol Ther, 2005,78（1）:81⁃88. doi: 10.1016/j.clpt.2005.03. 004.
［49］	Gimenez F, Foeillet E, Bourdon O, et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects［J］. Clin Pharmacokinet, 2004,43（10）:685⁃692. doi: 10.2165/00003088⁃200443100⁃00004.

[1]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[2]	郭昊刘辉张丽朱冠男王平姚志荣高兴华陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814.
[3]	付丹丹李佳林付修宇张芯育胡华宋向凤田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844.
[4]	陈春里闫思聿王丹高丽华谭丽娜唐四元刘伟曾金容鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831.
[5]	荆可王媛李锁冯素英. 表现为环状红斑水疱的自身免疫性表皮下水疱病25例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 832-838.
[6]	王珊王星宇舒虹张斌石航杨欢钱秋芳马红艳梁源赵牧童申春平焦磊田晶汪洋谷盈孙婧刘盈李萍王华马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821.
[7]	申春平李萍罗晓燕梁源刘盈赵牧童王珊田晶焦磊汪洋罗珍余时娟方晓王华马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762.
[8]	徐西利李东宁段函王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750.
[9]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[10]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[11]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.
[12]	王俊霞郭伟楠陈慧郝军峰李冰卫静宜赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765.
[13]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[14]	王莉任增果娄桂予张玉薇杨科雷星星张冰廖世秀郝冰涛. 两个营养不良型大疱性表皮松解症家系的基因诊断[J]. 中华皮肤科杂志, 2023, 56(8): 770-773.
[15]	唐志铭荆梦晴陆鹭单霄张翠侠张晓宇孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650.

吗替麦考酚酯治疗免疫相关性皮肤病专家建议

Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

Metrics

本文评价

推荐阅读 10